Sort
82,697 grants matching “vaccine development”
A polymeric biomaterial-based vaccine utilizing immunomodulatory agents and antigen for the amelioration of type 1 diabetes.
$989,307Benjamin Michael Looney · Onevax, Llc · R44 · FY2020 · DK
Universal Attenuated Sporozoite Vaccine and Challenge System
$989,298Stephen Lev Hoffman · Sanaria, Inc. · R44 · FY2016 · AI
Cytokines in AIDS and Cancer Immunotherapy
$989,274George N. Pavlakis · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency
$989,251Alan S. Wayne · Children'S Hospital Of Los Angeles · U01 · FY2023 · AI
PEDIATRIC AIDS CLINICAL TRIAL UNIT
$989,191Univ Of Massachusetts Med Sch Worcester · U01 · FY2002 · AI
Improved bacterial strains for therapeutic DNA and protein production
$989,190Frederick R Blattner · Scarab Genomics, Llc · R44 · FY2009 · GM
The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis
$989,186Chetan Seshadri · University Of Washington · R01 · FY2025 · AI
Development of an H2O2-inactivated chikungunya virus vaccine
$989,109Ian James Amanna · Najit Technologies, Inc. · R44 · FY2019 · AI
Preclinical development of novel small molecule malaria drugs that overcome drug
$989,081David H Peyton · Designmedix, Inc. · R42 · FY2014 · AI
Vaccine and Treatment Evaluation Units (VTEU)
$989,030Hana M El Sahli · Baylor College Of Medicine · UM1 · FY2021 · AI
An RSV Prefusion F Vaccine that Overcomes Immunosenescence
$989,026Mark Yondola · Calder Biosciences, Inc. · R44 · FY2021 · AG
Novel immunotherapy against MOG antibody disease
$988,943Weston Daniel · Evoq Therapeutics, Inc. · R44 · FY2025 · TR
Antibody-based Protection against Flavivirses
$988,938Michael S. Diamond · Washington University · R01 · FY2018 · AI
Development of Coccidioides Cytokine Release Assay
$988,914Eric Holbrook · Miravista Diagnostics, Llc · R44 · FY2025 · AI
Vaccine and Treatment Evaluation Units: Overall Administration, Clinical Operations Support, Protocol Development, Implementation and Assays
$988,828Robert Frenck · Cincinnati Childrens Hosp Med Ctr · N01 · FY2020 · AI
Complete Genome Variation in Africans with Extreme HIV-1 Transmission Phenotypes
$988,775Jairam Rao Lingappa · University Of Washington · R01 · FY2011 · AI
PfSPZ Vaccine for Prevention of Plasmodium falciparum malaria
$988,772Stephen Lev Hoffman · Sanaria, Inc. · U44 · FY2022 · AI
Intranasal Vaccine Against Lyme Disease
$988,528Maria Gomes-Solecki · Immuno Technologies, Inc. · R44 · FY2022 · AI
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
$988,498David I Watkins · Mabloc, Llc · R42 · FY2022 · AI
Dendritic Cell-Targeted HIV Vaccine Product
$988,487Tibor Keler · Celldex Therapeutics, Inc. · R44 · FY2015 · AI
Chimeric Alphavirus Vaccines for Chikungunya
$988,452Scott C Weaver · University Of Texas Med Br Galveston · U01 · FY2009 · AI
Leveraging Bio-Cultural Mechanisms to Maximize the Impact of Multi-Level Preventable Disease Interventions with Southwest Populations
$988,400Flavio Francisco Marsiglia · Arizona State University-Tempe Campus · U54 · FY2022 · MD
Human Genetic Analysis Resource
$988,394Robert C. Elston · Case Western Reserve University · P41 · FY2010 · RR
Fogarty AIDS International Training &Research Program
$988,380Johns Hopkins University · D43 · FY2003 · TW
A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR1
$988,360Erol Fikrig · L2 Diagnostics, Llc · R42 · FY2022 · AI